title: Guideline for postmarketing Chinese medicine pharmacoeconomic evaluation.
abstract: Pharmacoeconomics is an important part of the postmarketing Chinese medicine (CM) evaluation, and postmarketing pharmacoeconomic evaluation can reveal the clinical and market value of CM. The purpose of establishing the guideline for pharmacoeconomic evaluation is to make the evaluation process and results regarding Chinese patent medicines both scientific and fair. Every country's guidelines for pharmacoeconomic evaluation act as reference guidelines, we have already drawn up the guideline that takes into account the special characteristics of CM; and these are in preparation for the postmarketing CM pharmacoeconomic evaluation.
authors.affiliation: Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, 100700, China.
authors.forename: Xin
authors.initials: X
authors.lastname: Wang
authors.forename: Zhi-Fei
authors.initials: ZF
authors.lastname: Wang
authors.forename: Yan-Ming
authors.initials: YM
authors.lastname: Xie
authors.forename: Wen
authors.initials: W
authors.lastname: Zhang
authors.forename: Xing
authors.initials: X
authors.lastname: Liao
authors.forename: Yan-Peng
authors.initials: YP
authors.lastname: Chang
mesh_terms: D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D017850:Economics, Pharmaceutical; D017408:Guidelines as Topic; D006801:Humans; D004364:Pharmaceutical Preparations / Q000191:economics; D011358:Product Surveillance, Postmarketing / Q000191:economics*; D013223:Statistics as Topic
chemical_list: D004364:Pharmaceutical Preparations